Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Coherus Bio
(NQ:
CHRS
)
2.070
+0.070 (+3.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,879,760
Open
2.020
Bid (Size)
2.030 (3)
Ask (Size)
2.060 (3)
Prev. Close
2.000
Today's Range
1.950 - 2.090
52wk Range
1.430 - 8.340
Shares Outstanding
112,714,488
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
April 08, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Why Coherus Biosciences Stock Tumbled on Thursday
March 14, 2024
The company fell well short of expectations for its fourth quarter.
Via
The Motley Fool
Performance
YTD
-34.08%
-34.08%
1 Month
-15.51%
-15.51%
3 Month
-13.75%
-13.75%
6 Month
-41.69%
-41.69%
1 Year
-74.66%
-74.66%
More News
Read More
Recap: Coherus BioSciences Q4 Earnings
March 13, 2024
Via
Benzinga
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
March 13, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Earnings Preview For Coherus BioSciences
March 12, 2024
Via
Benzinga
Earnings Scheduled For March 13, 2024
March 13, 2024
Via
Benzinga
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
March 05, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Completes Divestiture of Ophthalmology Franchise
March 04, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
February 23, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
February 21, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Why Coherus BioSciences Stock Jumped Today
February 06, 2024
Via
The Motley Fool
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
February 05, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Why Coherus BioSciences Stock Is Sinking Today
January 23, 2024
Via
The Motley Fool
Why Coherus Biosciences Popped Today
January 22, 2024
Via
The Motley Fool
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 22, 2024
Via
Benzinga
Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?
January 22, 2024
Via
Benzinga
Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today?
January 22, 2024
Via
InvestorPlace
Why Is B. Riley Financial (RILY) Stock Down 11% Today?
January 22, 2024
Via
InvestorPlace
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Why Is Coherus BioSciences (CHRS) Stock Up 17% Today?
January 22, 2024
Via
InvestorPlace
Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
January 22, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
January 22, 2024
Via
InvestorPlace
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
January 22, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 18, 2024
Via
Benzinga
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
January 18, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.